Related Experiment Video
Updated: Jun 12, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C
Soo Ryang Kim1, Susumu Imoto, Masatoshi Kudo
1Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
Abstract:
We describe a 72-year-old woman with chronic hepatitis C and autoimmune thrombocytopenic purpura (AITP) during pegylated interferon (PEG-IFN) alpha. Immunoglobulin G and antinuclear antibody were 2,113 mg/dL and 1,280 at the start, respectively. A liver biopsy negated autoimmune hepatitis. After a 48-week combination therapy with ribavirin, PEG-IFN alpha-2a was administered. At the 30th month, the platelet count was decreased to 1.1 x 10(4)/microL. Bone marrow biopsy disclosed normocellular marrow compatible with AITP. The platelet-associated IgG (PAIgG) titer rose to 500 ng/10(7) cells. Corticosteroid therapy was successful, and the platelet count and PAIgG titer reverted to 6.4 x 10(4)/microL and 57.3 ng/10(7) cells, respectively.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Viral Hepatitis I: Introduction
Venous Thrombosis III: Interprofessional Care
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...

